{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:30:48Z","timestamp":1792416648777,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":2111,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/modpathol.2016.221","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T07:43:02Z","timestamp":1483688582000},"page":"577-586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Emeka K","family":"Enwere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth N","family":"Kornaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora A","family":"Koulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kalantarian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"K\u00f6bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafull","family":"Ghatage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M","family":"Magliocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan P","family":"Lees-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne M","family":"Doll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/modpathol.2016.221_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1038\/modpathol.2016.221_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5306\/wjco.v5.i2.86","article-title":"Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB","volume":"5","author":"Minig","year":"2014","journal-title":"World J Clin Oncol"},{"key":"10.1038\/modpathol.2016.221_bib3","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1200\/JCO.2008.16.4368","article-title":"Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials","volume":"26","author":"Chemoradiotherapy for Cervical Cancer Meta-Analysis C","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/modpathol.2016.221_bib4","first-page":"858","article-title":"Programmed death 1 immune checkpoint inhibitors","volume":"13","author":"Trivedi","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1038\/modpathol.2016.221_bib5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2016.221_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1038\/modpathol.2016.221_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2016.221_bib8","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2016.221_bib9","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/0008-5472.CAN-12-2384","article-title":"Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma","volume":"73","author":"Lyford-Pike","year":"2013","journal-title":"Cancer Res"},{"key":"10.1038\/modpathol.2016.221_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12105-012-0406-z","article-title":"B7-H1 expression model for immune evasion in human papillomavirus-related oropharyngeal squamous cell carcinoma","volume":"7","author":"Ukpo","year":"2013","journal-title":"Head Neck Pathol"},{"key":"10.1038\/modpathol.2016.221_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/ERC-12-0313","article-title":"Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation","volume":"20","author":"Cunha","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"10.1038\/modpathol.2016.221_bib12","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1038\/modpathol.2016.221_bib13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1038\/modpathol.2016.221_bib14","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2016.221_bib15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaoncol.2015.6326","article-title":"Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva","volume":"2","author":"Howitt","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1038\/modpathol.2016.221_bib16","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","article-title":"The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer","volume":"22","author":"Gevensleben","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2016.221_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","article-title":"High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis","volume":"59","author":"Finkelmeier","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1038\/modpathol.2016.221_bib18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3892\/or.2015.4435","article-title":"Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8(+) T cells","volume":"35","author":"Leng","year":"2016","journal-title":"Oncol Rep"},{"key":"10.1038\/modpathol.2016.221_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2015.11.020","article-title":"Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy","volume":"55","author":"Tokito","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1038\/modpathol.2016.221_bib20","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.ijrobp.2012.06.021","article-title":"The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis","volume":"85","author":"Doll","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/modpathol.2016.221_bib21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13058-015-0575-2","article-title":"Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer","volume":"17","author":"Feng","year":"2015","journal-title":"Breast Cancer Res"},{"key":"10.1038\/modpathol.2016.221_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2326-6066.CIR-14-0133","article-title":"PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer","volume":"3","author":"Wimberly","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1038\/modpathol.2016.221_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1038\/modpathol.2016.221_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2307\/2532051","article-title":"A concordance correlation coefficient to evaluate reproducibility","volume":"45","author":"Lin","year":"1989","journal-title":"Biometrics"},{"key":"10.1038\/modpathol.2016.221_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ygyno.2013.11.015","article-title":"PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma","volume":"132","author":"McIntyre","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1038\/modpathol.2016.221_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"10.1038\/modpathol.2016.221_bib27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PAI.0000000000000256","article-title":"Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer","volume":"23","author":"Phillips","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1038\/modpathol.2016.221_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40425-015-0059-z","article-title":"The therapeutic promise of disrupting the PD-1\/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors","volume":"3","author":"Romano","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1038\/modpathol.2016.221_bib29","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/modpathol.2016.221_bib30","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"issue":"328","key":"10.1038\/modpathol.2016.221_bib31","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Science Translational Medicine"},{"key":"10.1038\/modpathol.2016.221_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"10.1038\/modpathol.2016.221_bib33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/modpathol.2016.64","article-title":"Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix","volume":"29","author":"Heeren","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1038\/modpathol.2016.221_bib34","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1158\/1078-0432.CCR-09-1652","article-title":"Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma","volume":"15","author":"Karim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/modpathol.2016.221_bib35","first-page":"31","article-title":"Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting","volume":"10","author":"Garcia-Teijido","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"10.1038\/modpathol.2016.221_bib36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jtho.2016.01.015","article-title":"The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer","volume":"11","author":"Bremnes","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1038\/modpathol.2016.221_bib37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12307-011-0066-7","article-title":"Immunosuppressive tumor microenvironment in cervical cancer patients","volume":"4","author":"Piersma","year":"2011","journal-title":"Cancer Microenviron"},{"key":"10.1038\/modpathol.2016.221_bib38","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1038\/modpathol.2016.221_bib39","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1038\/modpathol.2016.221_bib40","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ijms17071046","article-title":"PD-L1 immunohistochemical detection in tumor cells and tumor microenvironment: main considerations on the use of tissue micro arrays","volume":"17","author":"Botti","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1038\/modpathol.2016.221_bib41","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/modpathol2016221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2016221","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222019834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395222019834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/modpathol2016221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:56:12Z","timestamp":1760230572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395222019834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0893395222019834"],"URL":"https:\/\/doi.org\/10.1038\/modpathol.2016.221","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/modpathol.2016.221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}